Chiome BioscienceChiome Bioscience Inc.4583東証グロース医薬品FY ending Dec 2025, non-consolidated, J-GAAP
Revenue by business segment, and the profit each one keeps.
Geographic revenue reported in annual filings
No geographic revenue breakdown was disclosed.
※ Segment figures include inter-segment sales and do not sum to the company total
X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.
Margin data is available for 1 businesses. At least two are needed for comparison.
| Segment | Revenue CAGR | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|---|
| Drug Discovery and Development | — | 103-1173.9% | — | — | 203-401.0% | — |
| Drug Discovery Support | +4.4%5y | 61052.4% | 63155.3% | 68258.4% | 57853.6% | 59359.9% |
Top: revenue. Bottom: operating margin.
EDINET (FSA Japan)
有価証券報告書－第22期(2025/01/01－2025/12/31)
EDINET (FSA Japan)
有価証券報告書－第21期(2024/01/01－2024/12/31)
EDINET (FSA Japan)
訂正有価証券報告書－第20期(2023/01/01－2023/12/31)
EDINET (FSA Japan)
有価証券報告書－第19期(2022/01/01－2022/12/31)
EDINET (FSA Japan)
有価証券報告書－第18期(令和3年1月1日－令和3年12月31日)
EDINET (FSA Japan)
有価証券報告書－第17期(令和2年1月1日－令和2年12月31日)
Extracted from XBRL: 41 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.